Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113972

Purification of a distinct placental lactogen receptor, a new member of the growth hormone/prolactin receptor family.

M Freemark and M Comer

Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710.

Find articles by Freemark, M. in: PubMed | Google Scholar

Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710.

Find articles by Comer, M. in: PubMed | Google Scholar

Published March 1, 1989 - More info

Published in Volume 83, Issue 3 on March 1, 1989
J Clin Invest. 1989;83(3):883–889. https://doi.org/10.1172/JCI113972.
© 1989 The American Society for Clinical Investigation
Published March 1, 1989 - Version history
View PDF
Abstract

Recent findings from this laboratory suggest that the biological actions of placental lactogen (PL) in mammalian fetal tissues are mediated through binding of the hormone to a distinct and unique PL receptor. We have now purified this receptor from fetal and maternal sheep liver, characterized its binding to PL, growth hormone (GH), and prolactin (PRL), and determined its molecular weight by SDS-PAGE and by affinity cross-linking techniques. Soluble extracts containing specific, high-affinity (Kd 0.5 nM) PL binding activity were prepared by incubating ovine fetal and maternal liver microsomes with 1% Triton X-100. The detergent solubilized PL receptor was purified two- to threefold by ion-exchange chromatography and an additional twofold by gel exclusion chromatography on Sepharose 6B. The PL receptor was then purified 75,000- to 125,000-fold by affinity chromatography using a column of ovine PL (oPL) coupled to Affi-Gel 10. The molecular weight of the oPL receptor as determined by SDS-PAGE and by cross-linking techniques was 44,000 +/- 2,000 (range 40,000-48,000). The purified receptor bound 125I-oPL specifically and with high affinity (Kd 0.5 nM) but did not bind either radiolabeled ovine GH or ovine PRL. In addition, in competition studies using 125I-oPL as the radioligand, the purified PL receptor bound unlabeled oPL with a potency 30-50 times greater than that of ovine GH and 500-1,000 times greater than that of ovine PRL. These findings demonstrate the presence of a specific PL receptor in fetal and maternal sheep liver. The PL receptor, together with the GH and PRL receptors, constitute a family of distinct but related hormone receptors that differ in their relative affinities for PL, GH, and PRL. Changes in the expression of the three receptors may mediate changes in the hormonal control of growth during the transition from fetal to postnatal life.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 883
page 883
icon of scanned page 884
page 884
icon of scanned page 885
page 885
icon of scanned page 886
page 886
icon of scanned page 887
page 887
icon of scanned page 888
page 888
icon of scanned page 889
page 889
Version history
  • Version 1 (March 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts